1. Home
  2. PTGX vs GKOS Comparison

PTGX vs GKOS Comparison

Compare PTGX & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Protagonist Therapeutics Inc.

PTGX

Protagonist Therapeutics Inc.

HOLD

Current Price

$88.83

Market Cap

5.4B

Sector

Health Care

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$116.63

Market Cap

5.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PTGX
GKOS
Founded
2006
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
5.4B
IPO Year
2016
2015

Fundamental Metrics

Financial Performance
Metric
PTGX
GKOS
Price
$88.83
$116.63
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
13
Target Price
$90.56
$126.38
AVG Volume (30 Days)
1.0M
735.2K
Earning Date
11-06-2025
10-29-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.72
N/A
Revenue
$209,217,000.00
$469,820,000.00
Revenue This Year
N/A
$31.15
Revenue Next Year
$288.98
$24.15
P/E Ratio
$123.35
N/A
Revenue Growth
N/A
30.38
52 Week Low
$33.70
$73.16
52 Week High
$96.54
$163.71

Technical Indicators

Market Signals
Indicator
PTGX
GKOS
Relative Strength Index (RSI) 53.99 74.84
Support Level $84.11 $115.07
Resistance Level $90.00 $118.17
Average True Range (ATR) 3.31 3.10
MACD -0.75 0.01
Stochastic Oscillator 38.05 87.55

Price Performance

Historical Comparison
PTGX
GKOS

About PTGX Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: